Proposal of Director Candidates and Changes to Representative Directors at the 150th Annual General Meeting of Shareholders

Overview of Director Candidates and Representative Director Changes

Takeda Pharmaceutical Company Limited announced that at the 150th Annual General Meeting of Shareholders scheduled for June 24, 2026, Julie Kim will be proposed as the new President and CEO, and will assume office upon approval. The current President and CEO, Christophe Weber, will resign as of the same date. Additionally, three candidates for outside directors—Bruce Broussard, Koichiro Kimura, and Paul Stoffels—will be proposed, with six outside directors scheduled to resign. All other incumbent directors will be proposed for reappointment.

Background and Expectations for New Director Candidates

The new outside director candidate Bruce Broussard is interim CEO of HP Inc. and possesses extensive management experience in the healthcare sector. Koichiro Kimura is a former group leader of PwC Japan Group with strengths in addressing geopolitical risks. Paul Stoffels is a co-founder of Galapagos and former Chief Scientific Officer at Johnson & Johnson, having led innovative pharmaceutical development. The Board expects these new candidates to contribute to strengthening supervisory and advisory functions during this transformative period for the company.